Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis
about
Intravenous Treatment with a Long-Chain Omega-3 Lipid Emulsion Provides Neuroprotection in a Murine Model of Ischemic Stroke - A Pilot StudyOmega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products.Switching from EPA + DHA (Omega-3-acid Ethyl Esters) to High-Purity EPA (Icosapent Ethyl) in a Statin-Treated Patient with Persistent Dyslipidemia and High Cardiovascular Risk: A Case Study.Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA)FlexPro MD, a Mixture of Krill Oil, Astaxanthin, and Hyaluronic Acid, Suppresses Lipopolysaccharide-Induced Inflammatory Cytokine Production Through Inhibition of NF-κB.Improving lipids with prescription icosapent ethyl after previous use of fish oil dietary supplements.Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients.Genetic variants of PTGS2, TXA2R and TXAS1 are associated with carotid plaque vulnerability, platelet activation and TXA2 levels in ischemic stroke patients.Long-Term Effects of Unprovoked Venous Thromboembolism on Mortality and Major Cardiovascular Events.Red Blood Cell Eicosapentaenoic Acid Inversely Relates to MRI-Assessed Carotid Plaque Lipid Core Burden in Elders at High Cardiovascular Risk.A novel cost-effectiveness model of prescription eicosapentaenoic acid extrapolated to secondary prevention of cardiovascular diseases in the United States.Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?Review of Cardiometabolic Effects of Prescription Omega-3 Fatty Acids.Synergistic Effect of Eicosapentaenoic Acid on Antiproliferative Action of Anticancer Drugs in a Cancer Cell Line Model.Effect of Dietary Components from Antarctic Krill on Atherosclerosis in apoE-Deficient Mice.Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study.Eicosapentaenoic Acid as a Potential Therapeutic Approach to Reduce Cardiovascular Risk in Patients with End-Stage Renal Disease on Hemodialysis: A Review.Effect of Eicosapentaenoic and Docosahexaenoic Acids Added to Statin Therapy on Coronary Artery Plaque in Patients With Coronary Artery Disease: A Randomized Clinical Trial.Impact of Adding Eicosapentaenoic Acid to Statin Therapy on Plasma Pentraxin 3 Level in Patients with Stable Coronary Artery Disease: A 6-Month, Randomized Controlled Study.Associations between thromboxane A synthase 1 gene polymorphisms and the risk of ischemic stroke in a Chinese Han population.Eicosapentaenoic acid ethyl ester improves endothelial dysfunction in type 2 diabetic mice.Relationship between circulating VCAM-1, ICAM-1, E-selectin and MMP9 and the extent of coronary lesions.The Eye, Oxidative Damage and Polyunsaturated Fatty Acids.Changes in Nutrient Profile and Antioxidant Activities of Different Fish Soups, Before and After Simulated Gastrointestinal Digestion
P2860
Q36208295-683BC88F-5FE1-40B9-AFE5-703182113659Q37099337-CE6B71F8-AC2D-4B2D-9011-900AC039CB68Q37118744-68E0380A-92FE-4BC0-93B3-55135186DA40Q37615904-D964F66D-B9E8-4EB1-986D-B5B0C19F42D8Q37645550-11BC66A9-D6CF-461A-BDF7-9345440C2396Q38882294-FCF68195-D55B-4526-B5C8-D55C1830603EQ38967706-0E5AB73E-5375-40C4-B7E7-117DD297297AQ40995784-67303812-0D5A-44B5-BE91-732DAA3A6BC8Q41104410-BFBC9638-7BD9-42EE-9408-6C856C59A085Q42368269-59507A3C-53E1-4AD6-9C04-2943A903E325Q45061743-712368DE-7F92-4D14-8073-A30667256377Q46962453-B816D525-487D-4750-9467-73DB0716ECBFQ47633216-AA173552-C0EF-4C08-882B-7496758BA78FQ47797570-9F9D7158-7FE6-4799-B130-001A5D18D96EQ47947045-08A3729C-3945-4F18-8B1F-9D6B1D0CD95EQ48173359-CE176B28-202F-46DF-B88C-589F92F25C3DQ49266738-023C23B4-D905-45FE-AF92-56648F2810FCQ49371179-3498737A-EF0C-44A2-B3F8-A2785E82BA6DQ51364877-1A318C96-C1DA-4061-B642-99C61E4D0C53Q52603047-84294892-E291-4108-B6BC-EA72328B05BAQ55037874-679E6BDA-F510-4F49-8606-107AB3A04174Q55037934-80BDA59B-F280-41AA-9827-2222220D9699Q55515186-F3BF1F78-56DF-4397-B7BC-71F79104A580Q58697335-7111BA27-8697-48AF-855E-491740D7DA6E
P2860
Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis
description
2015 nî lūn-bûn
@nan
2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Biologic plausibility, cellula ...... acid (EPA) in atherosclerosis
@ast
Biologic plausibility, cellula ...... acid (EPA) in atherosclerosis
@en
Biologic plausibility, cellula ...... acid (EPA) in atherosclerosis
@nl
type
label
Biologic plausibility, cellula ...... acid (EPA) in atherosclerosis
@ast
Biologic plausibility, cellula ...... acid (EPA) in atherosclerosis
@en
Biologic plausibility, cellula ...... acid (EPA) in atherosclerosis
@nl
prefLabel
Biologic plausibility, cellula ...... acid (EPA) in atherosclerosis
@ast
Biologic plausibility, cellula ...... acid (EPA) in atherosclerosis
@en
Biologic plausibility, cellula ...... acid (EPA) in atherosclerosis
@nl
P2093
P3181
P1433
P1476
Biologic plausibility, cellula ...... acid (EPA) in atherosclerosis
@en
P2093
John R Nelson
Kenneth M Borow
R Preston Mason
P304
P3181
P356
10.1016/J.ATHEROSCLEROSIS.2015.07.035
P407
P577
2015-09-01T00:00:00Z